Imfinzi addition to BCG therapy significantly improved DFS in high-risk NMIBC patients, with a 32% reduction in DFS events. The study involved 1,018 patients, with three cohorts receiving different ...
Source: Getty Images BCG shortages and the fragile BCG supply chain created a bladder cancer treatment vacuum. For more than 40 years, intravesical bacillus Calmette-Guérin (BCG) has been the mainstay ...
In this phase IIb parallel cohort study, patients with BCG-unresponsive carcinoma in situ (CIS) with/without papillary disease received TAR-200 monotherapy (Cohort 2 [C2]), TAR-200 plus cetrelimab (C1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback